BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioMarin Pharma (BMRN) Posts Q4 Loss of $0.53
February 23, 2017 4:04 PM ESTBioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.53), which may not compare to the analyst estimate of ($0.38). Revenue for the quarter came in at $300 million versus the consensus estimate of $295.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
... More